Avibactam prodrug - Pfizer
Alternative Names: AV-006Latest Information Update: 28 May 2023
At a glance
- Originator Arixa Pharmaceuticals
- Developer Pfizer
- Class Amides; Antibacterials; Azabicyclo compounds; Heterocyclic bicyclo compounds; Small molecules; Sulfates
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Bacterial-infections in Australia (PO)
- 14 May 2019 Arixa Pharmaceuticals has patent protection for prodrugs covering broad composition of matter patent (Arixa Pharmaceuticals pipeline, May 2019)
- 01 May 2019 Arixa Pharmaceuticals plans a phase I trial for Bacterial Infections (In volunteers) in June 2019 in Australia (NCT03931876)